CD1C and neoplasm: Conversely, CD1c+ mDCs, cells with an inferior capacity to cross-present antigen to CD8+ T cells compared with CD141+ DCs, were increased in tumor tissue, but the differences were at the expense of non-pCR patients (Fig. 4D) and PLN patients (Fig. 4D).